Caxton Associates (New York)’s Health Catalyst HCAT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
– Sell
-14,773
Closed -$157K – 553
2022
Q4
$157K Buy
+14,773
New +$143K 0.01% 398
2021
Q3
– Sell
-5,098
Closed -$283K – 505
2021
Q2
$283K Buy
+5,098
New +$272K 0.03% 330

Other funds holding HCAT

Caxton Associates (New York)'s HCAT Position: Q1 2023 in Review

Caxton Associates (New York) sold out of Health Catalyst (HCAT) in Q1 2023, closing a stake of 14,773 shares — an estimated $157K sold.

Caxton Associates (New York) first reported a position in HCAT in Q2 2021 and held it in 2 quarters. The position peaked at $283K in Q2 2021. 161 funds tracked by Wall St. Rank hold HCAT as of Q1 2023.

  • Caxton Associates (New York) reported no remaining Health Catalyst position as of Q1 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 14,773 Health Catalyst shares in Q1 2023, an estimated $157K.
  • Caxton Associates (New York) first reported a position in Health Catalyst in Q2 2021 and held it in 2 quarters.
  • Caxton Associates (New York)'s Health Catalyst position peaked at $283K in Q2 2021.
  • 161 funds tracked by Wall St. Rank held Health Catalyst as of Q1 2023.

Based on Caxton Associates (New York)'s 13F filing for Q1 2023, filed 15 May 2023.